Margherita Ambrosini, Medical Doctor, Oncology Clinical and Research Fellow at the Fondazione IRCCS National Cancer Institute in Milan, Italy:
“In this review we go through the key aspects that characterize MSI-H/dMMR cancers, in light of recent diagnostic advances and the successes of immune checkpoint inhibitors in both advanced and early stage disease.
Have a look!”
“Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers.”
Authors: Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taieb, Filippo Pietrantonio
